Tech Company Financing Transactions
Reneo Pharmaceuticals Funding Round
Reneo Pharmaceuticals, based in San Diego, secured $50 million from New Enterprise Associates, Lundbeckfond Ventures and Pappas Ventures.
Transaction Overview
Company Name
Announced On
5/21/2019
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from the Series A will be used to support ongoing Phase 1b clinical trials, as well as other clinical and preclinical studies.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
12230 El Camino Real 230
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Not Recorded
Overview
Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gregory Flesher
Chief Medical Officer
Alejandro Dorenbaum
Chief Operating Officer
Wendy Johnson
VP - Operations
Lynn Purkins
Browse more venture capital transactions:
Prev: 5/21/2019: Siemplify venture capital transaction
Next: 5/21/2019: Tiled venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs